Oncomed Pharmaceuticals Inc (OMED) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access OMED Annual Balance Sheets →
The balance sheet data below highlights changes in Oncomed Pharmaceuticals Inc's financial position over recent quarters.
Quarterly Report, GAAP in USD millions
ITEM
(Dec 31 2018)
(Sep 30 2018) (Jun 30 2018) (Mar 31 2018) (Dec 31 2017)
Assets
Cash & cash equivalent9.69
Short-term Investments, Total47.66
Cash & Short-term Investments56.00
Accounts receivable3.03
Other Current Assets1.44
Prepaid Expense And Other Assets Current1.91
Total Current Assets63.73
Equipment/Property/Plant Net0.62
Other Assets, Noncurrent0.73
Total Assets65.08
Liabilities
Accounts Payable, Current AC1.79
Accrued Liabilities, Current AC4.37
Other Liabilities, Current6.43
Deferred Revenue, Current DE0.06
Total Current Liabilities12.64
Total Long-term Debt0.00
Deferred credits, Noncurrent4.10
Accrued Income Taxes, Noncurrent AC10.00
Other liabilities, Noncurrent0.10
Accrued Clinical Liabilities Current2.74
Total Liabilities16.85
Stockholders' Equity
Common Stock Value0.04
Additional Paid In Capital Common Stock410.01
Retained Earnings / Accumulated Deficit-361.79
Other Equity-0.03
Common Stockholder's Equity48.23
Total Stockholder's Equity48.23
Liabilities & Stockholder's Equity65.08
4 historic quarters locked

Sign in to unlock the full Oncomed Pharmaceuticals Inc balance sheet history.

About OMED Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

  • Form: 10-Q
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.